New imaging agent could shed light on Cholesterol's role in disease

NCT ID NCT04532489

Recruiting now Knowledge-focused Sponsor: Benjamin Viglianti Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study is testing a new radioactive tracer called [18F]FNP-59 to see if it can safely and clearly image cholesterol in the adrenal glands using PET scans. Six healthy volunteers will receive a tiny, non-therapeutic dose of the tracer. The goal is to improve imaging for conditions like high blood pressure that involve cholesterol trafficking.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FNP-59 (a radioactive tracer for PET scans)
What this could lead to: If successful, this could lead to a better imaging method to study cholesterol-related conditions like high blood pressure or adrenal disorders.
What could go wrong: This is a very early, small study with only 6 healthy participants, so it may not translate to patients. The tracer's safety and effectiveness are still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHOLESTEROL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHOLESTEROL HYPERTENSION RADIOTRACER

Contacts and locations

Locations

University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.